Sana Biotechnology will present data from several

0

SEATTLE, May 02, 2022 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company specializing in the creation and delivery of engineered cells as medicines, today announced that five abstracts covering preclinical data from his hypoimmune and fusogenic platforms have been accepted for oral or poster presentation at the American Society of Gene and Cell Therapy (ASGCT) 25and Annual Meeting May 16-19, 2022 in Washington, DC

“We will have a strong presence at ASGCT, with data presentations from multiple technology platforms, including two oral presentations on our hypoimmune platform and two posters on our fusogenic platform,” said Steve Harr, MD, President and CEO of Sana. “We remain excited about the progress we are making with these platforms which aim to address some of the major challenges faced in the field of gene and cell therapy. Our goal is to file two INDs this year from two of these platforms, with the goal of translating our exciting scientific advances into therapies that benefit patients.

ASGCT summaries are publicly available at https://annualmeeting.asgct.org.

Oral presentations:
Title: Primary pancreatic islet cells from hypoimmune mice functionally survive and rescue allogeneic diabetic mice
Summary: Hypoimmune islet cells transplanted intramuscularly may be able to persist and function in diabetic patients without immune suppression
Abstract number: 1244
Session: Cell therapies for hematological disorders
Date hour : Thursday, May 19, 2022 from 10:30 a.m. to 10:45 a.m. ET
Title: Generation of ready-to-use allogeneic hypoimmune Tregs
Summary: A method to genetically engineer immune evasive ‘hypoimmune’ regulatory T cells (Tregs) ex-vivo which, in the tests tested, are immunoevasive, functional and protected from innate immune reactivity
Abstract number: 1254
Session: Engineering, development or manufacturing of cell therapy products
Date hour : Thursday, May 19, 2022 from 11:15 a.m. to 11:30 a.m. ET
Poster presentations:
Title: Fusosomes re-targeted for in vivo delivery to T cells
Summary: invivo delivery of CD19 CAR transgene payload with vectors targeting CD8 or CD4 in Nalm-6 tumor-bearing mouse models demonstrated robust production and persistence of CAR T cells, leading to tumor eradication
Abstract number: 1081
Session: Cancer – Immunotherapy, Cancer Vaccines III
Date hour : Wednesday, May 18, 2022 from 5:30 p.m. to 6:30 p.m.
Title: Fusosome-targeted gene transfer to human hepatocytes
Summary: Proof of principle data showing efficient delivery of a reporter transgene to human hepatocytes live using a humanized liver mouse model
Abstract number: 875
Session: RNA virus vectors
Date hour : Wednesday, May 18, 2022 from 5:30 p.m. to 6:30 p.m. ET
Title: A new VCN assay that detects lentiviral vector integrations while overcoming limitations caused by plasmid residues
Summary: Data from a new assay that relies on a unique digital amplicon and droplet PCR process that is specific only to reverse-transcribed self-inactivating viral vector nucleic acids
Abstract number: M-305
Session: Pharmacological/toxicological studies or assay development
Date hour : Monday, May 16, 2022 from 5:30 p.m. to 6:30 p.m. ET

About the Hypoimmune Platform
Sana’s hypoimmune platform is designed to create cells ex-vivo which can “hide” from the patient’s immune system to allow allogeneic cell transplantation without the need for immunosuppression. We apply hypoimmune technology to both pluripotent stem cells, which can then be differentiated into multiple cell types, and donor-derived allogeneic T cells, with the goal of making potent and persistent CAR T cells at scale. Preclinical data demonstrates across a variety of cell types that these transplanted allogeneic cells are able to evade both the innate and adaptive arms of the immune system while retaining their activity. Our most advanced programs using this platform include an allogeneic CAR T program targeting CD19+ cancers and stem cell-derived pancreatic cells for patients with type 1 diabetes.

About the Fusogen Platform
Sana is developing retargetable fusogens as a platform technology to enable the live delivery of genetic payloads to specific cell types. Fusogens can bind to cell surface proteins on the target cell type and, when combined with delivery vehicles to form fusosomes, deliver genetic payload directly to the cell’s cytoplasm. We have shown in preclinical studies that we can engineer fusogens to specifically target various cell surface receptors that allow for cell-specific delivery across several different cell types. Our most advanced programs using this platform include live CAR T cell fusosome product candidates targeting CD19+ cancer cells, including non-Hodgkin’s lymphoma, chronic lymphocytic leukemia and acute lymphocytic leukemia.

About Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicine for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and bringing our therapies to patients at scale. We are a group of passionate people working together to create a sustainable business that is changing the way the world treats disease. Sana has operations in Seattle, Cambridge, South San Francisco and Rochester. For more information about Sana Biotechnology, please visit https://sana.com/.

Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding Sana Biotechnology, Inc. (the “Company”, “we”, “us” or “our”) within the meaning of the federal securities laws, including those relating to the views of the company, progress and business plans; expectations regarding its development programs, product candidates and technology platforms, including its preclinical, clinical and regulatory development plans and timing expectations; the Company’s participation in the 2022 meeting of the American Society of Gene & Cell Therapy and the subject of the Company’s presentations at that meeting; the potential ability to make modified hypoimmune pluripotent stem cells and allogeneic donor-derived T cells that survive and evade the immune system without immunosuppression and the potential efficacy of these hypoimmune cells; and the potential ability to design retargetable fusogens that specifically target cell surface receptors that, when combined with delivery vehicles, enable cell-specific delivery across different cell types. All statements other than statements of historical facts contained in this press release, including, without limitation, statements regarding strategy, expectations, cash flow and future financial condition, future operations and outlook of the Company, are forward-looking statements. In some cases, you can identify forward-looking statements by words such as “intends”, “anticipates”, “assumes”, “believes”, “intends”, “continues”, “could”, “conceives”, “due, “”estimate”, “expect”, “goal”, “intend”, “may”, “goal”, “plan”, “positioned”, “potential”, “predict”, “seek “,” “should,” “target,” “will,” “would,” and other similar expressions that predict or indicate future events and future trends, or the negative form of these or other comparable terms. Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections regarding future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and needs. In light of the significant uncertainties in these d forward-looking statements, you should not rely on forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including, among others, risks inherent in drug development such as those associated with initiation, cost, timing, progress and results of the Company’s current and future activities. research and development programs, preclinical and clinical trials, as well as economic, market and social disruptions due to the current COVID-19 health crisis. For a detailed discussion of risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC filings, including, but not limited to, its Annual Report on Form 10. -K dated March 16, 2022. required by law, the Company undertakes no obligation to publicly update any forward-looking statements for any reason.

Investor Relations and Media:
Nicole Keith
Investor.relations@sana.com
media@sana.com

Share.

Comments are closed.